Phico Therapeutics is developing a unique antibiotic technology to address one the most urgent challenges facing medicine today â€“ how to destroy multi-drug resistant bacteria, the so-called â€œsuperbugsâ€.
Phicoâ€™s patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. SASPjectâ„¢ is a new class of antibiotic which could provide many advantages over conventional antibiotic classes.
Funding Rounds (1) - $1.63MUpdate
|Apr 28, 2010||businessweekly.co.uk - Phico Therapeutics raises 1630571 in unknown round|
Babraham Research Campus
Cambridge, CB22 3AT